Report #2832651

Received Mar 21, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: NY
Recovered: Unknown
Vaccinated: Nov 22, 2024
Onset: Mar 5, 2025
Days to onset: 103
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	—	—

Symptoms (1)

Herpes zoster

Symptom narrative

shingles; This non-serious case was reported by a other health professional via call center representative and described the occurrence of shingles in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On 22-NOV-2024, the patient received the 1st dose of Shingrix. On 05-MAR-2025, 103 days after receiving Shingrix, the patient experienced shingles (Verbatim: shingles). The outcome of the shingles was unknown. It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK Receipt Date: 16-MAR-2025 The patient received dose of Shingrix vaccine and developed Shingles. The reporter was ask when should receive the second dose of Shingrix vaccine.